← Back to Search

Oxazolidinone Antibiotic

Tedizolid for Osteomyelitis

Phase 2
Waitlist Available
Led By Loren G Miller, MD MPH
Research Sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 16-24 weeks
Awards & highlights

Study Summary

This trial will study whether tedizolid is a tolerable, safe, and effective treatment for bone and joint infections caused by MRSA.

Eligible Conditions
  • Osteomyelitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~16-24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 16-24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Quantify the Safety of Tedizolid for Bone and Joint Infections, Both Hardware and Non-hardware Associated
Quantify the Tolerability of Tedizolid for Bone and Joint Infections, Both Hardware and Non-hardware Associated
Secondary outcome measures
Number of participants with treatment-related adverse events as assessed by MedDRA v18.1
Other outcome measures
Number of Participants With an Outcome of "Cure" as Defined as no Need for Further Antibiotics Beyond the Originally Planned Duration Determined by the Participant's Primary/Treating Physician.

Side effects data

From 2021 Phase 2 trial • 44 Patients • NCT03009045
5%
Rash
100%
80%
60%
40%
20%
0%
Study treatment Arm
Drug: 200mg Oral Tedizolid

Trial Design

1Treatment groups
Experimental Treatment
Group I: Drug: 200mg oral TedizolidExperimental Treatment1 Intervention
200mg oral tablet of tedizolid to be taken once daily
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tedizolid
FDA approved

Find a Location

Who is running the clinical trial?

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterLead Sponsor
101 Previous Clinical Trials
46,257 Total Patients Enrolled
Loren G Miller, MD MPHPrincipal InvestigatorLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections (OTTER)
loren g miller 2017. "Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections (OTTER)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03009045.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top